BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33866340)

  • 1. Correlations of
    Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
    Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
    Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
    Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
    Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
    Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective correlation of
    Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
    Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of (
    Yilmaz U; Komek H; Can C; Altindag S
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Xue AL; Kalapara AA; Ballok ZE; Levy SM; Sivaratnam D; Ryan A; Ramdave S; O'Sullivan R; Moon D; Grummet JP; Frydenberg M
    J Urol; 2022 Feb; 207(2):341-349. PubMed ID: 34546815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
    Lv J; Yu H; Yin H; Shi Y; Shi H
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.